| Original language | English (US) |
|---|---|
| Pages (from-to) | 1131-1136 |
| Number of pages | 6 |
| Journal | International Journal of Radiation Oncology Biology Physics |
| Volume | 109 |
| Issue number | 5 |
| DOIs | |
| State | Published - Apr 1 2021 |
ASJC Scopus subject areas
- Radiation
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: International Journal of Radiation Oncology Biology Physics, Vol. 109, No. 5, 01.04.2021, p. 1131-1136.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Reducing Radiation-Induced Cognitive Toxicity
T2 - Sparing the Hippocampus and Beyond
AU - Redmond, Kristin J.
AU - Milano, Michael T.
AU - Kim, Michelle M.
AU - Trifiletti, Daniel M.
AU - Soltys, Scott G.
AU - Hattangadi-Gluth, Jona A.
N1 - Funding Information: Disclosures: K.J.R. reports personal fees from NCCN and Accuray Inc, travel expenses from Accuray, Inc, BrainLab, and Elekta AB, and research funding from Accuray Inc, and Elekta AB, outside the submitted work; and serving on the data safety monitoring board for Biomimetix. M.T.M. reports personal fees from Galera Therapeutics, AstraZeneca, and Wolters Kluwer, outside the submitted work. M.K. reports grants from Blue Earth Diagnostics, outside the submitted work. D.M.T. reports grants from BlueEarth Diagnostics and the Eveleigh Family Foundation, outside the submitted work. S.G.S. reports personal fees from Inovio Pharmaceuticals, Inc and Zap Surgical, Inc and grants from Novocure, outside the submitted work. J.H.-G. reports grants from National Institutes of Health, during the conduct of the study; and grants from Varian Medical Systems, outside the submitted work. The other authors declare no conflicts of interest. Funding Information: Disclosures: K.J.R. reports personal fees from NCCN and Accuray Inc, travel expenses from Accuray, Inc, BrainLab, and Elekta AB, and research funding from Accuray Inc, and Elekta AB, outside the submitted work; and serving on the data safety monitoring board for Biomimetix. M.T.M. reports personal fees from Galera Therapeutics, AstraZeneca, and Wolters Kluwer, outside the submitted work. M.K. reports grants from Blue Earth Diagnostics, outside the submitted work. D.M.T. reports grants from BlueEarth Diagnostics and the Eveleigh Family Foundation, outside the submitted work. S.G.S. reports personal fees from Inovio Pharmaceuticals, Inc and Zap Surgical, Inc and grants from Novocure, outside the submitted work. J.H.-G. reports grants from National Institutes of Health, during the conduct of the study; and grants from Varian Medical Systems, outside the submitted work. The other authors declare no conflicts of interest.
PY - 2021/4/1
Y1 - 2021/4/1
UR - http://www.scopus.com/inward/record.url?scp=85101922098&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101922098&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2021.01.001
DO - 10.1016/j.ijrobp.2021.01.001
M3 - Review article
C2 - 33714520
AN - SCOPUS:85101922098
SN - 0360-3016
VL - 109
SP - 1131
EP - 1136
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 5
ER -